• 提示：詳情請(qǐng)下載說(shuō)明書(shū)。

• 產(chǎn)品描述： CYC-116 is a potent aurora A and aurora B inhibitor with Kis of 8 and 9 nM, respectively.

• 靶點(diǎn)： Aurora A:8 nM (Ki);Aurora B:9.2 nM (Ki)

• 體內(nèi)研究：
  Oral administration of CYC-116 at dose levels of 75 and 100 mg/kg q.d. causes tumor growth delays of 2.3 and 5.8 days, which translates into specific growth delays of 0.32 and 0.81, respectively. The mean relative tumor volumes of mice receiving CYC-116 at both dose levels are less than those of vehicle-treated mice for the duration of the study period. At 100 mg/kg po q.d., the reduction in growth is statistically significant on days 6 and 9

• 參考文獻(xiàn)：
  1. Wang S, et al. Discovery of N-phenyl-4-(thiazol-5-yl)pyrimidin-2-amine aurora kinase inhibitors. J Med Chem. 2010 Jun 10;53(11):4367-78.

• 溶解性： DMSO  :  15  mg/mL  (40.71  mM;  Need  ultrasonic)    H2O  :  <  0.1  mg/mL  (insoluble)

• 保存條件： -20℃

• 配置溶液濃度參考：
  

  	1mg	5mg	10mg
  1 mM	2.714 ml	13.57 ml	27.14 ml
  5 mM	0.543 ml	2.714 ml	5.428 ml
  10 mM	0.271 ml	1.357 ml	2.714 ml
  50 mM	0.054 ml	0.271 ml	0.543 ml

• 注意：部分產(chǎn)品我司僅能提供部分信息，我司不保證所提供信息的權(quán)威性，僅供客戶參考交流研究之用。

• 1. [IF=5.988] Qun Wang et al."Study on the liver Drug’s dominant metabolic enzymes for six effective components of the Huang qi Liuyi decoction."Frontiers in Pharmacology.2023; 14: 1175896

輸入產(chǎn)品批號(hào)：

本計(jì)算器可幫助您計(jì)算出特定溶液中溶質(zhì)的質(zhì)量、溶液濃度和體積之間的關(guān)系，公式為：

質(zhì)量 (mg) = 濃度 (mM) x 體積 (mL) x 分子摩爾量 (g/mol)

• pg ng μg mg g kg =
  fM pM nM μM mM M *
  nL μL mL L *